Who We Are

At Immitra Bio, we combine two powerful technologies: hematopoietic stem cell therapies and CRISPR-Cas gene editing.

Jan - Ariya Bio

Dr. Jacob Corn

Chief Scientific Advisor & Co-Founder

Dr. Amir Taheri

CSO & Co-Founder

Jan Nelis

CEO & Co-Founder

Dr. Luigi Lerra

R&D Scientist

Mierelle Schuijt

R&D Scientist

As a Spin-Off of the Federal Institute of Technology in Zürich, we have strong ties to academia and benefit from an advanced support structure.

At Immitra Bio, we are committed to diversity, equity, and inclusion, and we believe that a diverse team is essential to push the boundaries of what is possible in the field of genetic engineering.

We are excited about the potential of our therapies to transform the lives of patients worldwide. Our goal is to bring cutting-edge therapeutics to patients around the world and to improve health outcomes for those affected. We are committed to working collaboratively with patients, families, and healthcare providers to ensure that our therapies meet their needs and expectations.